In a recent GlobalData survey, “The State of the Biopharmaceutical Industry 2024 (mid-year update)”, 73% of surveyed healthcare industry professionals felt optimistic or very optimistic about the industry’s growth during the next 12 months, up by 13% from the data received six months ago (60%) and up a further 13% from 2023 (47%), but still below the levels seen in 2022 (81%).
Structure Therapeutics’ GLP-1 receptor agonist GSBR-1290 achieved mean weight loss of 6.2% in overweight or obese patients. The company’s shares jumped to a six-month high on the news Monday.
Sanofi announced on Monday at the ASCO annual meeting that a combination treatment that includes its anti-CD38 monoclonal antibody Sarclisa had shown a positive effect in reducing disease progression and death in multiple myeloma patients. The news comes as Sanofi pushes for another indication for the drug.
Annexon said on Tuesday its experimental drug to treat a rare neurological disease met the main goal of a late-stage trial, sending its shares up more than 31% before the bell.
A panel of advisers to the U.S. Food and Drug Administration will meet today to discuss a therapy based on the psychedelic drug MDMA for patients with post-traumatic stress disorder (PTSD).
There are several other drug developers aiming to join the weight loss drug bandwagon. The following is a list of publicly listed companies targeting the next big blockbuster opportunity.